Titre
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Polesel, Jerry
Auteure/Auteur
Clifford Gary, M.
Auteure/Auteur
Rickenbach, Martin
Auteure/Auteur
Dal Maso, Luigino
Auteure/Auteur
Battegay, Manuel
Auteure/Auteur
Bouchardy, Christine
Auteure/Auteur
Furrer, Hansjakob
Auteure/Auteur
Hasse, Barbara
Auteure/Auteur
Levi, Fabio
Auteure/Auteur
Probst-Hensch Nicole, M.
Auteure/Auteur
Schmid, Patrick
Auteure/Auteur
Franceschi, Silvia
Auteure/Auteur
Groupes de travail
Swiss HIV Cohort Study (SHCS)
Liens vers les personnes
Liens vers les unités
ISSN
0269-9370
Statut éditorial
Publié
Date de publication
2008
Volume
22
Numéro
2
Première page
301
Dernière page/numéro d’article
306
Peer-reviewed
Oui
Langue
anglais
Résumé
OBJECTIVE: To assess the long-term effect of HAART on non-Hodgkin lymphoma (NHL) incidence in people with HIV (PHIV). DESIGN: Follow-up of the Swiss HIV Cohort Study (SHCS). METHODS: Between 1984 and 2006, 12 959 PHIV contributed a total of 75 222 person-years (py), of which 36 787 were spent under HAART. Among these PHIV, 429 NHL cases were identified from the SHCS dataset and/or by record linkage with Swiss Cantonal Cancer Registries. Age- and gender-standardized incidence was calculated and Cox regression was used to estimate hazard ratios (HR). RESULTS: NHL incidence reached 13.6 per 1000 py in 1993-1995 and declined to 1.8 in 2002-2006. HAART use was associated with a decline in NHL incidence [HR = 0.26; 95% confidence interval (CI), 0.20-0.33], and this decline was greater for primary brain lymphomas than other NHL. Among non-HAART users, being a man having sex with men, being 35 years of age or older, or, most notably, having low CD4 cell counts at study enrollment (HR = 12.26 for < 50 versus >or= 350 cells/microl; 95% CI, 8.31-18.07) were significant predictors of NHL onset. Among HAART users, only age was significantly associated with NHL risk. The HR for NHL declined steeply in the first months after HAART initiation (HR = 0.46; 95% CI, 0.27-0.77) and was 0.12 (95% CI, 0.05-0.25) 7 to10 years afterwards. CONCLUSIONS: HAART greatly reduced the incidence of NHL in PHIV, and the influence of CD4 cell count on NHL risk. The beneficial effect remained strong up to 10 years after HAART initiation.
Sujets
PID Serval
serval:BIB_5179FAB96939
PMID
Date de création
2008-04-10T14:14:15.013Z
Date de création dans IRIS
2025-05-20T14:59:33Z